JP2014513141A5 - - Google Patents

Download PDF

Info

Publication number
JP2014513141A5
JP2014513141A5 JP2014509519A JP2014509519A JP2014513141A5 JP 2014513141 A5 JP2014513141 A5 JP 2014513141A5 JP 2014509519 A JP2014509519 A JP 2014509519A JP 2014509519 A JP2014509519 A JP 2014509519A JP 2014513141 A5 JP2014513141 A5 JP 2014513141A5
Authority
JP
Japan
Prior art keywords
composition
hydrogen
subject
compound
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014509519A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014513141A (ja
JP6122420B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/036841 external-priority patent/WO2012154695A2/en
Publication of JP2014513141A publication Critical patent/JP2014513141A/ja
Publication of JP2014513141A5 publication Critical patent/JP2014513141A5/ja
Application granted granted Critical
Publication of JP6122420B2 publication Critical patent/JP6122420B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014509519A 2011-05-06 2012-05-07 多発性嚢胞疾患の治療 Active JP6122420B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161483630P 2011-05-06 2011-05-06
US61/483,630 2011-05-06
PCT/US2012/036841 WO2012154695A2 (en) 2011-05-06 2012-05-07 Treatment of polycystic disease

Publications (3)

Publication Number Publication Date
JP2014513141A JP2014513141A (ja) 2014-05-29
JP2014513141A5 true JP2014513141A5 (cg-RX-API-DMAC7.html) 2015-09-10
JP6122420B2 JP6122420B2 (ja) 2017-04-26

Family

ID=47139933

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014509519A Active JP6122420B2 (ja) 2011-05-06 2012-05-07 多発性嚢胞疾患の治療

Country Status (6)

Country Link
US (1) US20140066462A1 (cg-RX-API-DMAC7.html)
EP (1) EP2704723A4 (cg-RX-API-DMAC7.html)
JP (1) JP6122420B2 (cg-RX-API-DMAC7.html)
CN (1) CN103796655A (cg-RX-API-DMAC7.html)
CA (1) CA2835197A1 (cg-RX-API-DMAC7.html)
WO (1) WO2012154695A2 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006068760A2 (en) 2004-11-19 2006-06-29 The Regents Of The University Of California Anti-inflammatory pyrazolopyrimidines
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
CN113620978A (zh) 2014-09-11 2021-11-09 加利福尼亚大学董事会 mTORC1抑制剂
US10118890B2 (en) 2014-10-10 2018-11-06 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
US10623555B2 (en) 2016-09-27 2020-04-14 Hartford Fire Insurance Company Controlling a graphical user interface for workflow
FR3075795A1 (fr) * 2017-12-21 2019-06-28 Galderma Research & Development Nouveaux composes inhibiteurs de mtor
FR3075794A1 (fr) 2017-12-21 2019-06-28 Galderma Research & Development Nouveaux composes inhibiteurs de mtor
FI3788049T3 (fi) 2018-05-01 2023-05-30 Revolution Medicines Inc C40-, c28- ja c-32-liittyneitä rapamysiinianalogeja mtor-estäjinä
SG11202010560QA (en) 2018-05-01 2020-11-27 Revolution Medicines Inc C26-linked rapamycin analogs as mtor inhibitors
AU2023275778A1 (en) 2022-05-25 2024-12-12 Revolution Medicines, Inc. Methods of treating cancer with an mtor inhibitor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0523659D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
JP5788316B2 (ja) * 2008-07-08 2015-09-30 インテリカイン, エルエルシー キナーゼインヒビターおよび使用方法
US8476431B2 (en) * 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
ES2709108T3 (es) * 2009-08-17 2019-04-15 Intellikine Llc Compuestos heterocíclicos y usos de los mismos
EP2705181B1 (en) * 2011-05-04 2016-12-21 Intellikine, LLC Combination pharmaceutical compositions and uses thereof

Similar Documents

Publication Publication Date Title
JP2014513141A5 (cg-RX-API-DMAC7.html)
JP2013542247A5 (cg-RX-API-DMAC7.html)
JP2012144574A5 (cg-RX-API-DMAC7.html)
JP2014507477A5 (cg-RX-API-DMAC7.html)
JP2013542261A5 (cg-RX-API-DMAC7.html)
JP2013510120A5 (cg-RX-API-DMAC7.html)
JP2012512907A5 (cg-RX-API-DMAC7.html)
JP2014500861A5 (cg-RX-API-DMAC7.html)
JP2010515715A5 (cg-RX-API-DMAC7.html)
JP2012502037A5 (cg-RX-API-DMAC7.html)
JP2013537905A5 (cg-RX-API-DMAC7.html)
JP2008195730A5 (cg-RX-API-DMAC7.html)
JP2017008088A5 (cg-RX-API-DMAC7.html)
JP2012092110A5 (cg-RX-API-DMAC7.html)
JP2014521735A5 (cg-RX-API-DMAC7.html)
JP2014510729A5 (cg-RX-API-DMAC7.html)
JP2013509429A5 (cg-RX-API-DMAC7.html)
JP2013518056A5 (cg-RX-API-DMAC7.html)
JP2008533007A5 (cg-RX-API-DMAC7.html)
RU2013121788A (ru) Ингибиторы репликации вич
JP2015503540A5 (cg-RX-API-DMAC7.html)
JP2015528020A5 (cg-RX-API-DMAC7.html)
JP2011504903A5 (cg-RX-API-DMAC7.html)
JP2012532883A5 (cg-RX-API-DMAC7.html)
JP2015509075A5 (cg-RX-API-DMAC7.html)